

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DCKET NO.

210121.419C10

APPLICATION NO.

09 699,295

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

October 26, 2000

GROUP ART UNIT

1631

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Mike	AA 5,912,143	06/15/99	Bandman et al.	435	69.1	
	AB 6,225,054	05/01/01	Frudakis et al.	435	6	
	AC 6,329,505	12/11/01	Xu et al.	530	350	
	AD 6,344,550	02/05/02	Frudakis et al.	536	23.5	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
Mike	AE	EP 1033401 A2	09/06/00	EPO		
	AF	WO 99/06550	02/11/99	WIPO		
	AG	WO 99/31236	06/24/99	WIPO		
	AH	WO 01/25272	04/12/01	WIPO		
	AI	WO 01/34802	05/17/01	WIPO		
	AJ	WO 01/51628	07/19/01	WIPO		
	AK	WO 01/51633	07/19/01	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Mike	AL	Ahn and Kunkel, "The structural and functional diversity of dystrophin," <i>Nature Genetics</i> 3:283-291, April 1993.
	AM	Attwood, T.K., "The Babel of Bioinformatics," <i>Science</i> 290: 471-473, October 20, 2000.
	AN	Boon, T., "Toward a Genetic Analysis of Tumor Rejection Antigens," <i>Adv. Cancer Res.</i> 58:177-210, 1990.
	AO	Burgess et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <i>Journal of Cell Biology</i> 111: 2129-2138, November 1990.
	AP	Cawthon et al., "cDNA Sequence and Genomic Structure of <i>EV12B</i> , a Gene Lying with an Intron of the Neurofibromatosis Type 1 gene," <i>Genomics</i> 9: 446-460, 1991.
	AQ	Curti, B.D., "Physical barriers to drug delivery in tumors," <i>Critical Reviews in Oncology Hematology</i> 14:29-39, 1993.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
210121.419C10APPLICATION NO.  
09 699,295SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary.)

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

October 26, 2000

GROUP ART UNIT

1631

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
BA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
BB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

filed	BC	Dermer, G.B., "Another Anniversary for the War on Cancer," <i>Bio/Technology</i> 12: 320, March 1994.
	BD	Drexler, H. "Recent Results on the Biology of Hodgkin and Reed-Sternberg cells. II. Continuous Cell Lines," <i>Leukemia and Lymphoma</i> 9: 1-25, 1993.
	BE	Embleton, M.J., "Monoclonal Antibodies to Osteogenic Sarcoma Antigens," in <i>Monoclonal Antibodies and Cancer, Immunology Series</i> 23, Wright, Jr. G.L. (ed.), Marcel Dekker, New York, NY, 1984, pp. 181-207.
	BF	Freshney, R.I., <i>Culture of Animal Cells: A Manual of Basic Technique</i> , Alan R. Liss, Inc., New York, 1983, pp.3-4.
	BG	GenBank Accession No. AA533501, August 1, 1997.
	BH	GenBank Accession No. AC018804, February 11, 2003.
	BI	GenBank Accession No. AI804733, July 6, 1999.
	BJ	GenBank Accession No. AQ063365, July 30, 1998.
	BK	GenBank Accession No. AQ124119, August 31, 1998.
	BL	Geneseq (Derwent) Accession No. AAV68996, January 22, 1999.
	BM	Geneseq (Derwent) Accession No. AAL10921, December 7, 2001.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED

MAR 13 2008

TECH CENTER 1600/2900

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEUTILITY DOCKET NO.  
210121.419C10APPLICATION NO.  
09/699,295SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

APPLICANTS

Tony N. Fridakis et al.

FILING DATE

October 26, 2000

GROUP ART UNIT

1631

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CA						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
CB					

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

mm 2	CC	Genseq (Derwent) Accession No. AAL11383, December 7, 2001.
	CD	Genseq (Derwent) Accession No. AAL11455, December 7, 2001.
	CE	Genseq (Derwent) Accession No. AAL13620, December 7, 2001.
	CF	Genseq (Derwent) Accession No. AAL18685, December 7, 2001.
	CG	Genseq (Derwent) Accession No. AAL20282, December 7, 2001.
	CH	Genseq (Derwent) Accession No. AAL20354, December 7, 2001.
	CI	Genseq (Derwent) Accession No. AAL22489, December 7, 2001.
nick	CJ	Genseq (Derwent) Accession No. AAT96475, February 26, 1998.
ju 2	CK	Gerhold and Caskey, "It's the genes! EST access to human genome content," <i>BioEssays</i> 18(12): 973-981, 1996.
1	CL	Geysen et al., "Cognitive Features of Continuous Antigenic Determinants," <i>Journal of Molecular Recognition</i> 1(1): 32-41, 1988.
	CM	Gillies and Wesolowski et al., "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibod. Hybridomas</i> 1(1): 47-54, 1990.
	CN	Harris et al., "Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect," <i>Journal of the American Society of Nephrology</i> 6(4): 1125-1133, October 1995.
	CO	Hartwell et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs," <i>Science</i> 278: 1064-1068, November 7, 1997.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED

MAR 13 2003

TECH CENTER 1600/2900

FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.  
210121.419C10APPLICATION NO.  
09/699,295

APPLICANTS

Tony N. Frudakis et al.

FILING DATE

October 26, 2000

GROUP ART UNIT

1631

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary.)\*EXAMINER'S  
INITIAL

DOCUMENT NUMBER

DATE

NAME

CLASS

SUBCLASS

FILED DATE  
IF APPROPRIATE

DA

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

DOCUMENT  
NUMBER

DATE

COUNTRY

TRANSLATION

YES

NO

DB

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DC

Hsu, T.C., "Karyology of Cells in Culture," in Tissue Culture: Methods and Applications, Kurse, Jr et al. (eds.), Academic Press, New York, 1973, pp. 764-767.

DD

Jain, R. K., "Barriers to Drug Delivery in Solid Tumors," *Scientific American* 271(1): 58-65, July 1994.

DE

Johnstone and Thorpe (eds.), *Immunochimistry in Practice*, Second Edition, Blackwell Scientific Publications, Oxford England, 1987, pp 49-50.

DF

Lazar et al., "Transforming Growth Factor  $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," *Molecular and Cellular Biology* 8: 1247-1252, March 1988.

DG

Russell and Barton, "Structural Features can be Unconserved in Proteins with Similar Folds. An Analysis of Side-chain to Side-chain Contacts Secondary Structure and Accessibility," *J. Mol. Biol.* 244: 332-350, 1994.

DH

Tao and Morrison, "Studies of Aglycosylated Chimeric Mouse-Human IgG. Role of Carbohydrate in the Structure and Effector Functions Mediated by the Human IgG Constant Region," *Journal of Immunity* 143(8): 2595-2601, October 15, 1989.

DI

Venter et al., "Genome sequence analysis: scientific objectives and practical strategies," *Trends in Biotechnology* 10: 8-11, Jan/Feb 1992.

DJ

Walter, G., "Production of use of antibodies against synthetic peptides," *Journal of Immunological Methods* 88: 149-161, 1986.

DK

Wei et al., "Protection against mammary tumor growth by vaccination with full-length, modified human *ErbB-2* DNA," *Int. J. Cancer* 81: 748-754, 1999.

DL

Wells and Peitsch, "The chemokine information source: identification and characterization of novel chemokines using the WorldWideWeb and Expressed Sequence Tag Databases," *Journal of Leukocyte Biology* 61: 545-550 May 1997.

EXAMINER

DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED

MAR 13 2003  
TECH CENTER 1600/2500